Improvement in affinity and thermostability of a fully human antibody against interleukin-17A by yeast-display technology and CDR grafting

Veldhoen, 2017, Interleukin 17 is a chief orchestrator of immunity, Nat Immunol, 18, 612, 10.1038/ni.3742 Mi, 2011, Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-β1-dependent and -independent mechanisms, J Immunol, 187, 3003, 10.4049/jimmunol.1004081 Zhang, 2017, Antagonism of Interleukin-17A ameliorates experimental hepatic fibrosis by restoring the IL-10/STAT3-suppressed autophagy in hepatocytes, Oncotarget, 8, 9922, 10.18632/oncotarget.14266 Cui, 2017, Acta Pharm Sin B, 7, 532, 10.1016/j.apsb.2017.06.007 Mease, 2015, Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis, N Engl J Med, 373, 1329, 10.1056/NEJMoa1412679 Frieder, 2018, Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis, Ther Adv Chronic Dis, 9, 5, 10.1177/2040622317738910 Syed, 2017, Ixekizumab: a review in moderate to severe plaque psoriasis, Am J Clin Dermatol, 18, 147, 10.1007/s40257-017-0254-4 Miossec, 2012, Targeting IL-17 and TH17 cells in chronic inflammation, Nat Rev Drug Discov, 11, 763, 10.1038/nrd3794 Wang, 2017, Targeting IL-17 in psoriatic arthritis, Eur J Rheumatol, 4, 272, 10.5152/eurjrheum.2017.17037 Cui, 2019, Highlights of the 2nd International Symposium on Tribbles and Diseases: tribbles tremble in therapeutics for immunity, metabolism, fundamental cell biology and cancer, Acta Pharm Sin B, 9, 443, 10.1016/j.apsb.2018.12.007 Lerner, 2016, Combinatorial antibody libraries: new advances, new immunological insights, Nat Rev Immunol, 16, 498, 10.1038/nri.2016.67 Zhao, 2017, Recent advances in monoclonal antibody-based therapeutics, Acta Pharm Sin, 52, 837 Guan, 2015, Cancer metastases: challenges and opportunities, Acta Pharm Sin B, 5, 402, 10.1016/j.apsb.2015.07.005 Jiang, 2018, Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective, Acta Pharm Sin B, 8, 530, 10.1016/j.apsb.2018.04.005 Igawa, 2011, Engineering the variable region of therapeutic IgG antibodies, MAbs, 3, 243, 10.4161/mabs.3.3.15234 Chao, 2006, Isolating and engineering human antibodies using yeast surface display, Nat Protoc, 1, 755, 10.1038/nprot.2006.94 Baker, 2010, Immunogenicity of protein therapeutics: the key causes, consequences and challenges, Self Nonself, 1, 314, 10.4161/self.1.4.13904 Frenzel, 2016, Phage display-derived human antibodies in clinical development and therapy, MAbs, 8, 1177, 10.1080/19420862.2016.1212149 Lonberg, 2008, Fully human antibodies from transgenic mouse and phage display platforms, Curr Opin Immunol, 20, 450, 10.1016/j.coi.2008.06.004 Hou, 2018, Recent advances of phage display techniques for drug discovery, Acta Pharm Sin, 53, 1279 Bradbury, 2004, Antibodies from phage antibody libraries, J Immunol Methods, 290, 29, 10.1016/j.jim.2004.04.007 Ewert, 2003, Biophysical properties of human antibody variable domains, J Mol Biol, 325, 531, 10.1016/S0022-2836(02)01237-8 Ewert, 2004, Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering, Methods, 34, 184, 10.1016/j.ymeth.2004.04.007 Sun, 2013, Optimizing the host bacteria to make a large naive phage antibody library in the recombination system, Acta Pharm Sin, 48, 66 Chen, 2014, One-step zero-background IgG reformatting of phage-displayed antibody fragments enabling rapid and high-throughput lead identification, Nucleic Acids Res, 42, e26, 10.1093/nar/gkt1142 Ferreira, 1995, The assessment of antibody affinity distribution by thiocyanate elution: a simple dose-response approach, J Immunol Methods, 187, 297, 10.1016/0022-1759(95)00186-4 Garber, 2007, A broad range of Fab stabilities within a host of therapeutic IgGs, Biochem Biophys Res Commun, 355, 751, 10.1016/j.bbrc.2007.02.042 Sblattero, 2000, Exploiting recombination in single bacteria to make large phage antibody libraries, Nat Biotechnol, 18, 75, 10.1038/71958 Silacci, 2016, Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases, MAbs, 8, 141, 10.1080/19420862.2015.1093266 Pullen, 1986, Antibody avidity determination by ELISA using thiocyanate elution, J Immunol Methods, 86, 83, 10.1016/0022-1759(86)90268-1 Bottermann, 2016, Antibody-antigen kinetics constrain intracellular humoral immunity, Sci Rep, 6, 37457, 10.1038/srep37457 Wang, 2011, Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus, J Biol Chem, 286, 44218, 10.1074/jbc.M111.290783 Sela-Culang, 2013, The structural basis of antibody-antigen recognition, Front Immunol, 4, 302, 10.3389/fimmu.2013.00302 Kawa, 2011, The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan, MAbs, 3, 479, 10.4161/mabs.3.5.17228 Jung, 1997, Improving in vivo folding and stability of a single-chain Fv antibody fragment by loop grafting, Protein Eng, 10, 959, 10.1093/protein/10.8.959 Willuda, 1999, High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment, Cancer Res, 59, 5758 Lee, 2004, High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold, J Mol Biol, 340, 1073, 10.1016/j.jmb.2004.05.051 Holm, 1996, The FSSP database: fold classification based on structure-structure alignment of proteins, Nucleic Acids Res, 24, 206, 10.1093/nar/24.1.206 Weitzner, 2017, Modeling and docking of antibody structures with Rosetta, Nat Protoc, 12, 401, 10.1038/nprot.2016.180 Zaretsky, 2013, Directed evolution of a soluble human IL-17A receptor for the inhibition of psoriasis plaque formation in a mouse model, Chem Biol, 20, 202, 10.1016/j.chembiol.2012.11.012 Eisen, 2014, Affinity enhancement of antibodies: how low-affinity antibodies produced early in immune responses are followed by high-affinity antibodies later and in memory B-cell responses, Cancer Immunol Res, 2, 381, 10.1158/2326-6066.CIR-14-0029 Schier, 1996, Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site, J Mol Biol, 263, 551, 10.1006/jmbi.1996.0598 North, 2011, A new clustering of antibody CDR loop conformations, J Mol Biol, 406, 228, 10.1016/j.jmb.2010.10.030 McConnell, 2014, A general approach to antibody thermostabilization, MAbs, 6, 1274, 10.4161/mabs.29680 Jung, 1999, Selection for improved protein stability by phage display, J Mol Biol, 294, 163, 10.1006/jmbi.1999.3196 Steipe, 2004, Consensus-based engineering of protein stability: from intrabodies to thermostable enzymes, Methods Enzymol, 388, 176, 10.1016/S0076-6879(04)88016-9 Gong, 2009, Engineered human antibody constant domains with increased stability, J Biol Chem, 284, 14203, 10.1074/jbc.M900769200 Chennamsetty, 2009, Design of therapeutic proteins with enhanced stability, Proc Natl Acad Sci U S A, 106, 11937, 10.1073/pnas.0904191106 Schaefer, 2012, Transfer of engineered biophysical properties between different antibody formats and expression systems, Protein Eng Des Sel, 25, 485, 10.1093/protein/gzs039